Selecta Biosciences Secures $20,000,000 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c8179754-be09-4f8c-9de7-e8de9bf28c58 - Date
10/15/2014 - Company Name
Selecta Biosciences - Mailing Address
480 Arsenal St. Building One Watertown, MA 02472 USA - Company Description
Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. - Website
http://www.selectabio.com - Transaction Type
Venture Equity - Transaction Amount
$20,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
With strong financial support from both our current and new investors, we are now well positioned to rapidly advance our immune tolerance pipeline, including the lead program SEL-212, the first non-immunogenic treatment for refractory and tophaceous gout. - M&A Terms
- Venture Investor
